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Abstract 
Introduction: Over the last decade, global health policies and different research areas have focused on 
the relevance and impact of medicine shortages. Published studies suggest there have been difficulties 
with access to medicines since the beginning of the twentieth century. There have though been 
advances in our understanding and management of the problem. However, in view of global and 
regional health care concerns with shortages, we believe this phenomenon needs to be characterized 
and described more fully. This includes the types of medicines affected, possible causes, and potential 
strategies to address these. The aim of this scoping review was to identify, compare if possible, and 
characterize the recent literature about the situation of medicines shortages between countries, and 
provide different perspectives including a global context and national approaches to help address the 
situation. Methodology: A scoping study presented as a narrative review of the situation and findings 
principally based on published papers. Results: Based on the reported cases in the literature, a typology 
of medicines shortage and supply interruption episodes and their causes were proposed. National 
approaches to notify and manage the medicines shortages cases were described and classified by update 
frequency. In addition, principal differences between market and supply chain management 
perspectives of the situation were identified and global and countries’ perspectives were described. 
Conclusion: Policy makers require solutions that prevent those cases in which the population's health 
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is affected by episodes of medicine shortages and/or interruption in the supply chain. There is also a 
need to generate a glossary related to logistics management and the availability of medicines. This will 
be useful to understand and overcome shortages as well as recognize that potential solutions are not 
only related with actions linked to research, development and innovation but much wider. Overall, this 
paper can act as a basis for future discussions in this important area. 
 
1 Introduction 
The World Health Organization (WHO) defined “access to medicines” as a multidimensional problem 
in view of the rising prices of new medicines and persisting problems of medicine shortages among 
concerns (1). Other concerns include out-of-pocket payments, which are especially important in lower 
and middle income countries (LMICs) where expenditure of medicines can be up to 70% of total 
healthcare expenditure and potentially catastrophic for patients and their families if they become ill (1–
3). However, this is outside the scope of this paper which principally deals with issues of shortages of 
medicines. 
The last WHO Director-General report included a variety of terms in their recent report on global 
medicine shortages such as “shortage”, “scarcity” (only in the Spanish version), and “stock outs” (only 
in the English version) that demand a comprehensive approach across countries (1). Consequently, 
there is an urgent need to develop a set of terminologies related to the problems identified by countries 
regarding the continual availability of essential medicines. 
There are different situations leading to out of stock of medicines. Some of them can be solved without 
causing obstacles to health care provision or in the availability of the best therapeutic option, whilst 
others may require additional efforts and ways to overcome affected health conditions. There have 
been several important efforts to document countries’ experiences and potential ways forward to 
address concerns with medicine shortages. The study of ISAGS published in 2017 characterized and 
analyzed the situation among 8 South American countries: Bolivia, Chile, Colombia, Ecuador, 
Paraguay, Peru, Venezuela and Uruguay (4). In 2018, Bochenek et al. systematically characterized, 
compared, and evaluated current measures, as well as legislative and organizational frameworks, to 
address medicines shortages among a wide range of European and Western Asian countries (5). These 
included 20 countries of the European Union (EU) and the European Free Trade Association (EFTA) 
- Austria, Belgium, Croatia, the Czech Republic, Estonia, France, Greece, Hungary, Ireland, Italy, 
Latvia, Lithuania, Malta, Norway, Poland, Portugal, Slovakia, Slovenia, Spain and Switzerland. In 
addition, 8 non-EU/EFTA countries: Albania, Azerbaijan, Israel, Kosovo, Montenegro, Republic of 
Srpska (Bosnia and Herzegovina), Serbia and Turkey. 
Both publications involving descriptions from regions of the world had similar findings about formal 
definitions as well as strategies that have been developed to prevent or mitigate against medicine 
shortages. Both publications emphasized the urgent need to explore further the phenomena to identify 
mechanisms which introduce possible solutions for situations affected by medicine shortages, as well 
as facilitate the monitoring and assessing of signals and subsequent actions. However, there is a need 
to consolidate current findings to provide additional direction given current concerns building on the 
experiences of other countries including Australia, Canada and the US, as well as more recent research 
findings. (6–8) 
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Learning from other countries’ experiences should not be underestimated or underutilized in shaping 
local or national pharmaceutical policies (6–15). Lessons can be drawn from cross country 
comparisons, even if a given country’s characteristics do not perfectly correspond in terms of 
geographical location, size, demography, economy, or type of health care system. Consequently, the 
objectives of this paper are to consolidate current findings as well as characterize and describe more 
fully the situation across continents in order to provide further evidence about the types of affected 
medicines, identified causes, and potential strategies to address shortages. Subsequently, use the 
findings to provide suggestions to address this important topic. 
2 Materials and methods 
The design of this study is a scoping review. Scoping reviews have been useful to describe broad topics 
and an overview of diverse literature which includes different study designs and methodologies in the 
published and grey literature (16).  
Previous efforts have helped identify the main characteristics to describe the medicine shortage 
situation. These include potential definitions, general characteristics of the problem, description of 
information systems, potential and perceived causes of shortages, and implemented solutions (5,17–
22). We have built on this including the studies of Bochenek et al and ISAGS (4,5). 
2.1 Search Process 
2.1.1 First Step 
Figure 1 shows the search process. In 2017, eligible studies were first identified from a search of 
PubMed with the following general MeSH terms strategy “DRUG OR MEDICINE AND 
SHORTAGE”. The results were subsequently filtered by period of time (last five years from May 
2017). Subsequent references were filtered by title and abstract, taking into account representative 
descriptions of countries’ medicines shortage situation. 
Other grey literature was retrieved from websites of the World Health Organization, ministries of 
health and national health authorities. In addition, legal acts were including in the scoping review, as 
well as information gathered and disclosed within the public domain by organizations involved in 
pharmaceutical markets. 
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2.1.2 Second Step  
Figure 2 shows the search process for the update implemented in 2019. The same search strategy was 
used filtered by period of time (January 2016 until April 2019) to help in the recovery of additional 
eligible studies. The strategy was also translated into Portuguese and Spanish to run a search in Lilacs, 
a specific database for Latin America countries. 
To retrieve other potential studies, free text search terms and a snowball literature review was 
undertaken. We ran the term “SHORTAGE” with specific countries and continents including Africa, 
Australia, Canada, China, Costa Rica, Japan, Mexico, Panama and the United Kingdom. 
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2.2 Inclusion Criteria 
This review includes studies that describe medicines shortage situations within a large jurisdiction or 
system of care, and settings could be regional, national or international. 
2.3 Selection Process 
Two reviewers (EV, AA) performed screened abstracts based on the tittle/abstract review. The full text 
of potential eligible studies were retrieved if one or both authors thought they were relevant. 
Disagreements were resolved by discussion and, when necessary, including a third author (TB) in the 
discussion. 
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2.4 Data extraction 
Data extracted from each study included the authors and year of publication, jurisdictional level, 
existence of definitions, general characteristics of shortages, medicines involved, description of 
information systems including four categories of frequencies of shortages reports, potential and 
perceived causes of shortages, and possible implemented solutions. 
3 Results 
3.1 Description of studies 
By 2017, the literature review had identified 50 references to include in this scoping review, and by 
2019 another 6 new references where identified. Of these total 56 references, 9 studies with regional 
with a broad focus on Europe and Latin America. We found studies with country description of 
medicines shortage for one East Asia country (China), seven European countries (Belgium, Finland, 
France, Ireland, Slovenia, Spain, United Kingdom), two Latin America countries (Brazil and 
Venezuela); two North American countries (Canada and the United States); two Oceania countries 
(Australia and Fiji); and four Western Asia countries (Iran, Iraq, Jordan and Israel) (Table 1). 
Insert Table 1. 
Three of the identified papers had developed surveys addressed to ministries of health, state medicines 
agencies and local health authorities of various countries from three regions to discuss potential ways 
to address medicine shortages (4,5,23). One study described the characteristics of shortages and 
country definitions (19). Another regional study described the shortage situation from the perspective 
of hospital pharmacists and prescribers (17). 
The United States (US), is the country with most publications in the field (26 references), many of 
them describing the professionals’ perspective of the situation at the health care jurisdictional level 
(24–42). Another study performed a comparison of medicines shortages between two hospitals setting 
from Arabia Saudi and the United States (43). 
3.2 Contexts and Reasons of Medicines Shortage  
The description of the shortage situations may be associated with four principal causes or determinants, 
namely: market, supply chain management, manufacturing, and political issues (Table 2). 
Insert Table 2 
Some authors have concluded that these categories are interrelated and have one aspect in common,  
that is many cases are related to the availability of safe and effective medicines with low profitability 
or with low sales making them non-viable commercially (36,40,44). 
In South American countries, medicine shortages generally occur with mature products without 
suppliers in the market due to market viability, and correspond mostly to parenteral medicines with 
low profitability.(4) 
Some countries issue alerts about medicines that are simply not available on the market in their country 
even if there is enough money to pay for them within their health care systems (5).  
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Finally, Bochenek et al. 2018 (5) addressed an increasing amount of evidence where medicines were 
unavailable in countries even if the products complied with current regulations and were financed 
within the healthcare system. As a result, these situations show that ethical and political issues could 
be affecting the timely availability of first line therapeutic alternatives. These situations threaten the 
ability of clinicians and governments to fulfill their moral obligations to patients and society to provide 
benefit to patients, minimize harm and promote equity. 
Published studies in hospitals allow a better follow up of the health consequences of medicine shortages 
(20,45); which is more difficult in ambulatory care (29,31,34,46,47). This scoping review identified a 
number of published papers  describing inpatient challenges regarding medicine shortages in the United 
States (24–42). 
3.3  Medicines involved  
The characterization of supply shortages, their frequency, and the main groups of medicines affected 
among countries and regions are described in Table 3. The same characterization though is not made 
for the impact of shortages on patients’ health and health care systems. Descriptions in this respect 
generally correspond to descriptions of cases regarding either the impact of shortages on health 
conditions or medical specialties, or limitations in obtaining data and estimates made from surveys. 
Insert Table 3 
The shortage of essential medicines, including the active ingredients mostly used in injectable 
chemotherapy medicines, antibiotics and anesthesia, are causing growing concern across regions 
including Europe, North America, Asia and America. However, the problem is much broader, affecting 
other classes of medicines - mainly parenteral medicines (8,21,29,30,36,47–49) including anesthetics, 
nutrition and electrolyte solutions, enzyme replacement medicines, radiopharmaceuticals and 
antibiotics. The shortage of medicines has also been observed and documented for instance in 
Australia, Canada, China and Israel (36,50,51). Most of the published evidence from the countries of 
South America show that shortages can occur even with essential medicines and specially injectable 
forms (4) (Figure 3). 
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The most frequent group of medicines reported with shortages by country are the cardiovascular 
medicines in Canada and Belgium; nervous system medicines in Australia, China and Israel; and anti-
infective system medicines for most of the countries in South America (4,7,23,36,52).  
Brazil has reported the national shortage of penicillins (first line treatment) as a result of the lack of 
specific raw materials for their production in the international market. This episode was described 
because of the increased incidence of syphilis, including also congenital syphilis, during the last 5 years 
and the concern this causes (Figure 4). 
The alternative second line antibiotics to treat acquired syphilis and the partners of pregnant women in 
Brazil, i.e. doxycycline and ceftriaxone, have doses of between 8 and 15 days, and there are concerns 
with adherence in practice (53). 
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In France (25), supply shortages with 71 types of medicine were identified. According to the ATC 
classification (54), the most prevalent ones were antibiotics, oncological medicines, antidepressants, 
antipsychotics, tuberculosis medicines, vaccines and immunoglobulins.  
In Iran, at least 73 cases of medicine shortages were identified, among which 44% were essential.  
Potentially, they  impacted on the successful management of disease areas such as HIV, epilepsy, 
hemophilia, thalassemia and patients undergoing organ transplants (35). 
3.4 Definitions 
3.4.1 National definitions  
Table 4 contains definitions adopted by countries, considering some attributes with the formulation 
and agreement of potential definitions. 
Insert Table 4 - Countries definitions  
One of the most important findings of this scoping review is that consulted sources, literature and 
institutional websites, have identified a considerable number of countries that are introducing 
legislative actions to cope with and address  medicines shortages, and had included formal definitions 
or related terms of medicine shortages in their legislation.  
Recently, Bochenek et al (5) identified four countries in Europe with specific definitions, and ISAGS 
in 2017 (4) described three definitions for Latin American countries. This scoping review found 
progress in both regions, eight European countries and seven Latin America now have national 
medicine shortage definitions. In addition, by using free terms in the search strategies, we found 
definitions for one more region, North America (Canada and the US), and for one country, Australia 
(Table 4). There are two primary source of definitions: one from health authority  websites (Argentina, 
Australia, Brazil, Colombia, Spain, US, Uruguay, Norway (see table 4 and 5) and the other are surveys 
include in some studies (Belgium, Canada, France, Greece, Hungary and Italy) (5,7,23,25). 
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Few countries have currently established a specific definition that includes the term “shortages” alone 
or in combination with the terms “medicines” or “drug”. These include Belgium, Canada, Colombia, 
France, Hungary, Greece, Italy, Spain, and the US (Table 4).  
Some countries have used logistics and market related terms. These include Uruguay (declaration of 
interruption of sale or interruption of marketing), Argentina (medicines lacking), Croatia (disturbance 
on the medicines’ market), Norway (temporary disruption of a medicine`s marketing). Brazil uses the 
term “discontinuation” complemented with a term related to the temporality of the situation (definitive 
or unplanned or temporary shortage), whilst Italy (short supply) and Peru use three terms: “supply 
shortage”, “unavailable Pharmaceutical Products” and “pharmaceutical product with limited supply” 
(Table 4). 
The Food and Drug Administration (FDA) in the USs has focused more on aspects related to scarcity 
and established a definition as: “a period of time when the demand or projected demand for a medically 
necessary drug in the United States exceeds its supply” (55).  
Bolivia, Chile, Croatia, Ecuador, Greece, Hungary, Norway and Venezuela currently do not have an 
official definition of medicine shortage. These countries consider terms associated with medicine 
shortages but currently do not define the term medicine shortages (5). Finally, Venezuela differentiates 
scarcity as the situation in which there is insufficient quantity of a medicine to meet current demand 
and supply and shortage when the product is just not available (56). 
3.5 Countries approaches 
A new website at the European Medicines Agency (EMA) includes information about national 
legislation and local report mechanisms for 24 of the 30 European countries1. In South America, Brazil, 
Argentina and Uruguay have regulations that make the reporting of situations that could potentially 
lead to shortages mandatory. EMA also have a regulation to report these cases. 
Two qualitative studies have documented countries’ legislation and report mechanisms for three 
regions: Europe, Western Asia and South America (4,5). This scoping review described one new 
region, North America (7,57) . In addition, it was possible to include information from 12 new 
countries: Australia, Bulgaria, Canada, Czech Republic, Denmark, Finland, Germany, Iceland, 
Rumania, Sweden, United Kingdom, UK, and the US (6,7,36,55,58).  
3.5.1 Information systems and vigilance 
Countries are taking actions regarding legislation and reporting systems in public websites (Table 5). 
Most of them are at the National Regulatory Agency level (28 countries), whilst others are at the 
Ministry of Health or National Health System level (Colombia, Israel, Malta, Poland, Spain, 
Switzerland, UK and Uruguay). Five countries were documented by Bochenek et al in 2018 (5,48) 
where pharmacist professional organizations and other stakeholders are also involved in medicines 
shortages reports. Finally, Canada has a website operated by a telecommunication company (Table 5). 
Some of the main features of these systems include the frequency of updates, the obligation of 
pharmaceutical companies or marketing authorization holders to notify key stakeholder groups, and 
                                                 
1 European Medicines Agency. Medicine shortages. https://www.ema.europa.eu/en/human-regulatory/post-
authorisation/medicine-shortages 
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public institutions in charge of the database. To enhance our understanding of the characteristics of 
databases on medicine shortages in selected countries of Europe, Western Asia, North America and 
Latin America, all databases have been divided into four groups, depending on frequency of their 
updating: high (daily), medium (weekly), low (less often than weekly), and unspecified (Table 5). 
Most of the countries have only a national report system, where the Ministry of Health or the National 
Regulatory Agency manage the database and request mandatory reports. However, other countries have 
more than one system involved in the gathering information including professional associations in 
France, Ireland, Malta, Portugal, Spain and Switzerland *Table 5) (5). Finally, 12 of 40 countries have 
not reported databases on medicine shortage. These include 6 from Europe (Albania, Cyprus, 
Lichtenstein, Montenegro, Netherlands, Serbia), 7 from South America (Guyana, Suriname, Ecuador, 
Bolivia, Paraguay, Peru, Venezuela), and Azerbaijan from Western Asia. None of the databases 
reported affected health conditions, or the possible impact caused by the reported episode. 
Whilst European countries have mandatory reporting systems for shortages, this scoping review 
detected new information systems with high frequency of shortages reports including Australia, 
Canada and the US.  Some countries from Latin America and Europe have low or unspecified update 
frequency in their websites (Table 5). 
Insert Table 5 
3.5.2 Networks and Initiatives 
In 2014, the South American Council for Health from UNASUR issued a declaration on "Access to 
medicines and problems of medicines shortage", which stated that the shortage of medicines is a global 
and regional problem that manifests itself in diverse and changing ways, and with various effects since 
there is insufficient information to determine the magnitude and features of the problem (4). 
During 2016, several South American countries proposed to document the shortages situation of 
essential medicines in the region, and to formulate strategies as part of the South American Institute of 
Government in Health (ISAGS) actions for 2017. ISAGS, together with the Andean Health Organism 
(Hipólito Unanue Agreement), undertook a study which described the situation in the member 
countries of the Andean and South American regions (4). An analysis of the medicines shortage 
situation of essential medicines was developed through the collection of information on decisions 
related to the problem, types of medicines identified by each country, identified causes, protocols of 
approach, solutions implemented, management and impact indicators, as well as limitations and 
experiences both at the country and regional levels that may be relevant to help overcome the problem.  
In 2016, the research collaboration initiative funded by the European Union was started. It is named 
COST CA15105 - European Medicines Shortages Research Network - addressing supply problems to 
patients (Medicines Shortages). It aims to stimulate and develop scientific research as well as to 
propose solutions by end of 2020 (59,60). The COST CA15105 network encourages systematic sharing 
of information and research about shortages of medicines and nutritional products. It also aims to 
respond to the diverse interests of clinical, financial and patients’ quality of life, to achieve analytical 
clarity on the causes of shortages, to simulate appropriate decision making in manufacturing and the 
trade of medicines, to highlight legal and economic frameworks, to disclose disincentives in the supply 
chain, as well as to reflect on best coping practices to help ensure patients’ health is not compromised 
by ongoing shortages. 
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On the EU level, in 2016 the EMA and the Heads of Medicines Agencies (HMA) created an 
HMA/EMA Task Force on the Availability of Authorized Medicines for Human and Veterinary Use, 
aiming to provide strategic support and advice to tackle disruptions in the supply of human and 
veterinary medicines and to ensure their continued availability (61). The key priorities of the 
HMA/EMA Task Force included (i) looking at ways to minimize supply disruptions and avoid 
shortages; (ii) developing strategies to improve the prevention and management of shortages caused 
by disruptions in the supply chain; (iii) encouraging best practices within the pharmaceutical industry 
to prevent shortages; (iv) improving the sharing of information and best practices among EU regulatory 
authorities to better coordinate actions across the EU, and (v) fostering collaboration with key 
stakeholders and enhancing communication of supply problems to EU citizens. A set of documents 
was published by EMA to support regulators involved in coordinating the shortage situations due to 
good manufacturing practice (GMP) non-compliance. A public catalogue for shortages has been 
established by EMA2, which is designed to communicate clear information on shortages to patients, 
healthcare professionals and other stakeholders. 
4 Discussion 
4.1 Study Description 
We believe this scoping review is comprehensive as it describes regional and country contexts about 
medicine shortages and current perceptions form different stakeholder perspectives. Indexed literature 
from the last six years present important challenges regarding the health and economic implications 
caused by supply disruptions and medicines shortages (7,20,62,63). However, we are aware more 
research is needed to estimate the impact of medicine shoratges.  
The descriptive cases reported by the US identified parenteral and hospital medicines in supply 
disruptions and shortages; moreover, published studies from countries including Brazil help to estimate 
the health implications of shortages of essential antibiotics (34,38,40,41,64,65). Future research efforts 
are needed in order to compare the situation and impact between country and regional levels. 
4.2 Shortage Definitions and Global Context 
Some ministries and health authorities have developed important initiatives to the timely identification 
of potential medicine shortages alongside initiatives to manage episodes of interruption in the supply 
chain  (25,36,55,66,67). 
De Weerdt 2015 (19) identified some elements involved in the definitions, i.e. “supply”, “delivery”, 
“availability”, “permanent discontinuation of drugs”, and “time frame”, in order to consider a uniform 
definition for drug shortages among European countries. Definitions from Table 4 do not involve 
“delivery” and “availability” as these are not reflected in the current formal definitions. Instead, other 
common terms are included such as “market” and “lack”. 
 Other countries including France, Belgium, Italy, Spain, Brazil, and Colombia, have adopted a 
definition that includes the perspective of shortage and some aspects related to supply chain 
management and market determinates. However, it is worth mentioning that the US FDA defines the 
problem of medicines shortage only from the perspective of scarcity and also includes a lead time. In 
                                                 
2 European Medicines Agency - https://www.ema.europa.eu/en/human-regulatory/post-authorisation/medicine-
shortages/shortages-catalogue 
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addition, the US FDA unlike other countries including Brazil and France, states that they will never 
ask a producer to make medicines or change the amount of medicines to be manufactured as solutions 
for dealing with drug shortages. They do not see this as their role (55). 
A further finding is that currently only a few countries have included a specific period of time into their 
definition of a shortage situation. These include Australia, Belgium, France, Norway and Uruguay (4–
6,23,25). There are some differences based on the perspective of the definition with Belgium, France, 
Norway and Uruguay establishing the shortage situation in a specific point of the supply chain, for 
instance, community pharmacies, or hospital pharmacies, or wholesalers. These countries have 
included short periods of time, which varies from 72 hours to 30 days (Bochenek et al. 2018; Bocquet 
et al. 2017; Bogaert et al. 2015; ISAGS 2017). On the other hand, Australia defined a period of time 
of 6 months considering the lack of a medication in the whole country (6). In Uruguay, less  than 30 
days is an ”interruption of marketing” and more than 30 days is a “declaration of interruption of sale” 
(4). 
One more main feature of a specific shortage situation is the identity of the involved medicine, e.g. 
simvastatin (as an individual medicine) or the class of medicines (statins, lipid modulators). Shortages 
can also refer to a certain pharmaceutical form (e.g. injectable, capsule, or lotion), administration route 
(e.g. parenteral or oral), or a certain concentration or package size. The way the product episode is 
defined - broadly or narrowly - depends on the purposes of the analysis and the availability of 
information. 
It should be highlighted that in 2017, a set of two co-existing definitions had been proposed by the 
WHO. On the supply side: “A ‘shortage’ occurs when the supply of medicines, health products and 
vaccines identified as essential by the health system is in-sufficient to meet public health and patient 
needs. This definition refers only to products that have already been approved and marketed, in order 
to avoid conflicts with research and development agendas.” On the demand side: “A ‘shortage’ will 
occur when demand exceeds supply at any point in the supply chain and may ultimately create a 
‘stockout’ at the point of appropriate service delivery to the patient if the cause of the shortage cannot 
be resolved in a timely manner relative to the clinical needs of the patient” (68). The needs of patients 
about essential medicines are still important to link in with these definitions. 
The report of the Director General of the WHO presented at the last Assembly regarding the global 
shortage of medicines and access to them in 2018 (A71 / 12). This gives considerable relevance to 
situations that are recognized as a shortage of medicines, which coincide with those recently reported 
by South American countries (4,69). They show how different points of the medicines’ value chain are 
affected by concerns with demand, which are caused both by the lack of commercial attractiveness and 
by logistics, and supply factors that prevent having medicines in a timely manner. 
Whilst the title of the WHO’s report refers to the global scarcity of medicines, throughout the document 
the term “shortage” is being used (69). In general terms, the difference between the two terms 
(“scarcity of medicines” and “shortage of medicines”) can be minimal. However, it is worth specifying 
that "scarcity" refers only to those situations in which for a specific need the medication does not exist, 
while "shortage" covers those cases in which it is not possible to have the medicine in a timely manner. 
These latter problems are not solved by activities linked to research, development and innovation. 
Terms such as “availability” and “affordability” have also to be clearly distinguished to describe the 
shortage phenomena where these occur to avoid confusion and concentrate on appropriate activities to 
address the situation. 
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Regarding “availability”, at the jurisdiction/country level, this term usually implies that a medicine has 
marketing authorization and is marketed (can be bought or obtained from the health system). At the 
pharmacy level, this usually means that the medicine could be dispensed at demand or within a short 
period of time.  
In contrast, the term “affordability” refers to the extent the product is available at a reasonable 
price/cost for the patient or healthcare system considering the purchasing capacity of the individuals 
and/or the health system, and does not endanger the financial sustainability of the purchasers. As 
mentioned earlier, this is particularly important for patients in LMICs where there are currently high 
co-payments. Affordability is also a growing issue in medium to high income countries especially with 
regard to new cancer medicines and those for orphan diseases with ever increasing prices (9,13,70,71). 
The shortage of medicines is related with two main activities planned by the WHO to be implemented 
between 2019 and 2023. These include  (i) research and development of medicines, and (ii) supply 
chain management (72). Previous studies have reported essential medicines that need rapid solutions 
to address current concerns (4) i.e. the penicillins for syphilis and congenital syphilis. 
The description of cases, the identified causes, and definitions of medicine shortages, typically involve 
attributes that facilitate the identification of key solutions to address the main challenges of health 
conditions affected by the shortages. Currently, the specific actions described in the last version of 
WHO roadmap for 2019 -2023 (72) do not discuss ways of approaching, and possible solutions, to 
these cases, which is a concern.  
We have highlighted the difficulty of building a simple typology of medicine shortages based on the 
multiple possible combinations of criteria. It may be more useful to define a check-list of relevant 
criteria that allows the characterization of the episode and to predict/estimate the potential 
impact/effects according to the likely magnitude and length of the shortage. This again will be 
researched further in the future. 
4.3 Causes and characteristics of the context that determines the identified episode  
The causes and context that define the shortage episodes or interruptions in the supply chain are 
different from other areas of policy that affect medicine availability such as the non-availability of 
medicines without a marketing license, or those still in the research phase, or issues of affordability 
leading to a lack of reimbursement or funding. 
Overall, we believe medicine shortages can be defined according to several criteria (Figure 5). 
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In fact, shortages might have multiple causes. Some of the causes might have a sequential cause-effect 
relationship such as a reduction of future envisaged demand due to a reduction of the incidence of 
relevant diseases or reduced use due to the availability of new valued medicines replacing existing 
ones, which will negatively impact on future profitability. This might cause the manufacturer to stop 
investing in the manufacturing process and disregard safety concerns, which may in turn lead to an 
increase in side effects and subsequent closure of the manufacturing plant.  
Beyond an agreed single definition of medicine shortages, the concepts that could be developed must 
identify precisely the causes and points in the supply chain for which they apply. Topics such as 
"shortage episode" could be more related to causes included in the market and policy dimensions (Table 
2), or “interruption of supply chain episodes” for those situations caused or detected from the 
dimension of supply chain management. 
4.4 Global Framework 
Once a shortage episode is identified and characterized, including the population and health condition 
affected, the appropriate pharmaceutical and health policy tools, as well as rational management of 
medicines and their stocks, could help identify the most effective and efficient available intervention 
to address the problem. This could include fast tracking authorization and importation of the medicine 
or an equivalent from another country or recommending physicians to prescribe a substitute medicine; 
alternatively, potentially increasing reimbursed prices where profitability is a concern. Coordination 
of national efforts and international cooperation are urgently needed on various levels to address this, 
including UNASUR, the Andean Health Organism— Hipólito Unanue Agreement, the European 
Union, and the WHO. We will be following this up in the future as well. 
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There have been issues in Europe with older cancer medicines when the originator company has sold 
their molecule to a generic manufacturer and this was re-launched at a considerably higher price 
prompting potential counter measures (73–76). Such activities will also be followed up mindful of the 
need for manufacturers to make a profit for sustained supply. 
Overall, we believe specific strategies and solutions should be formulated at a national and global level. 
However, shortages must be clearly distinguished from scarcity. We believe this will lead to improved 
approaches to address episodes of medicine shortages and interruptions in the supply chain, as well as 
more pertinent solutions and their implementation to address current concerns.  
There is a growing interest in international cooperation in the area of medicine shortages research, its 
prevention and ways to facilitate actions that provide a timely response. For South American countries 
the development of a consensus to build or adapt a definition of medicines shortages demands the 
compilation of countries’ definitions in order to generate a glossary related to logistics management 
and the availability of medicines. Some approaches, such as risk management and a panel of logistical 
indicators for medicines, can be adapted to each country according to its complexities, including the 
health system, epidemiological alerts and geographical peculiarities. On a regional level, it has also 
been proposed to design a regional platform for horizon scanning and undertaking a pilot project to 
identify medicines that may be at risk of stock-outs, or possible withdrawals from the market, by 
reviewing the license status and reviewing databases related to imports and the pharmaceutical market. 
No less important is to develop pilots for those priority medicines that affect the population health in 
the region. 
4.5 Approaches to medicine shortages 
The proposed categorization of causes of medicines shortages can be used as guidance to find potential 
solutions, as well as considering the supply stage of medicines, market competition, and possible 
therapeutic substitutes. 
The Ministries and Health Authorities must consider which health conditions are affected by the 
shortage or supply chain interruption. This includes the proposed therapeutic use of the medicine and 
the availability of other therapeutic options, considering the optimal treatment for the disease or health 
condition involved within available resources. 
Maybe the most critical causes of medicine shortages are those related to market aspects because these 
situations depend on the will of the producer, seller or buyer, and the power relationship between each 
part. Some common situations are when a pharmaceutical company decides to suspend the production 
of a medicine, or the seller decides to modify the price of a specific pharmaceutical product, affecting 
its funding and supply. In view of this, possible solutions cannot just be focused on new possible 
innovations.  
Likewise, country initiatives shouldn´t just consist only of designing systems in order to compile 
information about cases of medicine shortages, they should look to include  specific interventions to 
address potential shortages as stated earlier. 
Other approaches could include the design and implementation of risk management programs that 
allow the anticipation of shortage episodes as well as implementing activities including horizon 
scanning in order to identify “programmed obsolescence” of a medicine represented as market 
withdrawals or changes in the pricing of products. We have seen horizon scanning and budgeting 
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successfully used in countries to better plan for the future, with Sweden and exemplar for other 
countries (9,77–79), and these activities are likely to grow. 
 On the other hand, problems related to supply chain management are focused on logistics management 
and the level of the supply chain or network. These problems can be mitigated through the design of 
health care supply chains, with objectives that look to maximize the service level (availability and 
accessibility) and optimize the financial component, with recent changes in the public system in South 
Africa a recent example among LMICs  (80). Ministries of Health should set key performance 
indicators for the country’s supply chain as well as implement improvements among the different 
agents in the supply chain over the different process including inbound and outbound transportation, 
fleet management, warehousing, materials handling, order fulfillment, logistics network design, 
inventory management, supply/demand planning, and the management of third party logistics services 
providers (81). This will help reduce shortages in the future. 
Some countries such as France (82) have implemented actions focused on logistic aspects including 
defining a dead line to establish supply interruptions and length of shortage episodes. France also 
established a decree in 2012 in order to overcome the dysfunctions of the pharmaceutical distribution 
channel based on supply chain interventions, as well as introducing constraining and coercive measures 
for the various actors in the distribution channel. The decree defines shortages as the inability for a 
community or hospital pharmacy to deliver a medicine to a patient within 72 hours if the medicine is 
currently not available as well as a possible therapeutic alternative if needed, or when supply 
difficulties may lead to a risk of public health for patients thereby creating an emergency. France 
established a procedure whereby all the actors of the medicine’s distribution channel should join forces 
to help address current concerns. The decree also established regulatory obligations for pharmaceutical 
companies including ensuring an appropriate and continuous supply of medicines to wholesalers to 
meet public and patients’ needs, implementing emergency call centers to inform agents about an 
anticipated or a current medicine shortage, informing the French authorities of emergency supplies, 
specifying the quantities and addresses, and informing of any risk concerns associated with any 
medicine shortage. The wholesaler must also declare its distribution territory, meet public obligations, 
have a selection of medicines at least nine-tenths of commercialized pharmaceutical products in France, 
and ensure to deliver medicines within 8 hours of any request (82) (25). However, there are still 
challenges especially in the field of major therapeutic interest medicines, and after seven years of the 
introduction of the decree there are still tensions between the agents of health supply chain in France 
due to other causes not related to supply chain management (83). 
5 Conclusions 
The descriptions of medicines shortage from the available literature in this scoping review allowed 
authors to extract the main characteristics as contexts and reasons of medicines shortage, the medicines 
involved, definitions, country information systems on shortages reports and alerts management, and 
finally the existence of networks between countries and stakeholders’ initiatives to suggest future 
strategies 
We believe our findings can help with the development of definitions related to the shortage of 
medicines that can be universally applied to prevent future confusion. We also believe this is first time 
such a comprehensive study reporting the most representative description of the current medicine 
shortage situation across multiple countries, and giving inputs regarding national and global health 
policies related to the most frequent reasons reported for medicine shortages, has been undertaken. 
This includes the description of the most likely medicine classes with shortages across countries, as 
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well as current national definitions and related terms as well as available databases to report medicine 
shortages. The study also describes frameworks and approaches among countries to help address these 
issues in the future. Overall we believe our findings can help with the development of definitions 
related to the shortage of medicines that can be universally applied in the future to prevent confusion. 
Signals linked with unattended or affected health conditions because of shortages must also be 
documented in order to establish improved interventions from a health authority perspective to ensure 
patients’ health is not compromised. Indeed, policy makers require solutions that prevent cases in 
which the population's health is affected by episodes of medicine shortages and/ or interruption in the 
supply chain. 
As part of this, we believe it is necessary to develop a consensus to build or adapt definitions of shortage 
and scarcity, as well as identifying all local definitions, in order to generate a glossary related to 
logistics management and the availability of medicines to better manage future situations.  We have 
started this process with this paper. 
We further believe it is important to emphasis that for those cases where shortages are due to logistical 
and supply factors, and it is not possible to have the medicines in a timely manner, that potential ways 
forward are not related to improving research, development and innovation as some bodies are 
proposing. This is a very different situation especially if alternative solutions are available including 
importation, permitting increased prices if pertinent along with advocating and documenting possible 
alternatives, and these must be explored first. 
Overall, we believe it would also be useful to identify options and best practices on how to address the 
most common causes of shortages and share these among all countries to provide future direction. 
These are research topics for the future building on this review across countries. 
Our findings show that part of the problem of shortages is focused on provision, especially those cases 
related to the permanent suspension of production or voluntary suspension due to for instance to the 
lack of commercial interest, either by low demand, the end of the patent, price regulations, use of 
compulsory licenses, and/ or the introduction of new medicines. Regarding suspending 
commercialization, it is important to review specific cases that have considerable public health 
concerns such as antineoplastic and antibiotics to suggest potential ways to overcome the situation. We 
have started this process and will continue. 
6 Limitations 
Whilst the findings presented in this study allows us to make comparisons between countries related 
with for instance national definitions and involved medicines, we are aware that there are other 
attributes that may well broaden the situation which we have not discussed. These can be addressed in 
future studies. 
7 Recommendations 
Further research is needed to assess the clinical and economic impact of medicines shortages at 
different jurisdictional levels, including hospital and outpatient levels. Additionally, cross country and 
regional studies will help to identify current essential medicines supply disruptions and shortages 
episodes which need prompt solutions. 
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Table 2. Most frequent reasons for medicine shortages 
Category Cause 
Market 
Increase in sales (40,82) 
Price-related aspects (40,44,52,82) 
Voluntary withdrawal (26,41,46,52,62) 
Unexpected increases and unexpected changes in clinical practice (41,52) 
Parallel or gray markets (52) 
Loss of market interest (7) 
Relocation of production facilities (7) 
Speculation in international markets (7) 
Mergers of manufacturers and joint purchasing group (7) 
Supply chain 
management 
Structure of the network or supply chain in the country (36) 
Supply of raw materials and excipients (25–27,36,41,42,46,82) 
Manufacturing 
process 
Quality concerns (25,26,36,41,42,49) 
Changes in the product formulation (26,52) 
Industrial development capacities (28,42,52,62) 
Production problems (7) 
Political and ethical 
issues 
Regulatory problems (25,27,36,40,42,46,52). 
Public policy (35,100,102). 
Social conflicts (5,35). 
Enhancement of the legal and normative frameworks applicable to the manufacture of medicines (7) 
 
 
Table 3. Description of Medicines Classes with Shortages in the selected countries 
Region / Country* Nervous system 
Cardiovascular 
system 
Anti-
infectives 
systemic 
Use 
Cancer 
Genitourinary 
system and sex 
hormones 
Alimentary 
track and 
metabolism 
South America 2017 17% 9% 21% 10% 7% Non Available 
Belgium 2009-2013 23% 21% 11% 9% Non Available 8% 
Israel 2013-2015 21% 15% 16% 
Non 
Available 
8% 7% 
US 2013-2017 18% 11% 
Non 
Available 
9% Non Available Non Available 
Canada (7) 31.8% 21.9% 8.5% 5.1% Non Available 0.1% 
Australia (6) 
12% (Anaesthetics) 
9% (Neurology) 
10% 20% 9.5% 10% Non available 
China (52) 13% 6% 6% 5.7% 11% 9% 
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Table 4. Countries definitions 
Country Terms/concepts 
 
Definition 
Argentina Medicines  lacking “known circumstances or facts that could jeopardize the supply of 
products and cause their temporary or definitive discontinuity in the 
market” 3 
Australia Shortage of a medicine “There is a shortage of a medicine in Australia at a particular time if, 
at any time in the 6 months after that particular time, the supply of that 
medicine in Australia will not, or will not be likely to, meet the 
demand for the medicine for all of the patients in Australia who take, 
or who may need to take, the medicine”4(6) 
Belgium Unavailability of medicines on the Belgian 
market 
“A drug is unavailable when enterprises that are responsible for the 
marketing of the drug are unable to deliver that drug for an 
uninterrupted period of four consecutive days to the community 
pharmacies, hospital pharmacies or wholesalers in Belgium.”(19) 
Brazil "Temporary discontinuation" 
 
 
 
 
"Definitive discontinuation"  
 
 
 
“Unplanned discontinuation of the manufacture 
or importation of medicines” 
of the manufacture or importation of medicines means that the license 
holder does not intend to cancel or does not to require the renewal of 
the registration of the product.  
 
of a product, in its turn, happens when the license holder intends to 
cancel or not request the renewal of the registration of the product.  
 
Are those cases where quality, efficacy or safety properties of 
medicines are affected and may lead to a supply shortage in the 
market. (4) 
Colombia Medicines shortage A situation which there is not enough supply to satisfy the demand of 
any medicine approved and market at the country.(66) 
Canada Drug shortage A situation in which an authorization holder for a drug is unable to 
meet the demand for the drug. Drug shortages can include temporary 
or permanent discontinuances in the production and supply of a drug 
(7) 
Croatia Disturbance on the medicines’ market Not specific. 
France Drug shortage A drug shortage is defined by law in France as an inability for a 
community pharmacy or a hospital pharmacy to deliver a drug within 
72 hours (102). Additionally, drug shortages in France have been 
classified formally into two separate contexts of either stock or supply 
problems. A stock-related shortage is defined as the lack of possibility 
to manufacture a medicine, whereas a supply-related shortage is 
defined as a problem in the distribution chain that makes the supply 
of a medicine impossible, even if enough of the medicine has been 
manufactured (19). 
Greece Actual shortages 
 
 
 
 
Temporary interruptions in supply 
“Pertains to the lack of capability to fulfill the demand and the non-
availability of a drug in the whole health care system, without the 
possibility to obtain that medicine from any source”. 
 
“ It refers to situations when drugs are not commercially available,” 
mainly for commercial reasons, for a limited time duration(5). 
Hungary “Drug shortage” As a term is reported to be widely used in the legislation, to report in 
case they are not able to supply, but without any association with a 
concrete formal definition (5). 
Italy Short supply The Italian Medicines Agency (AIFA) defines medicines in short 
supply as: “Medicines which are not available or not to be found on 
the whole Italian market, because the marketing authorization holder 
(MAH) is unable to guarantee the correct and regular supply to meet 
patients’ needs.” (5). 
Norway Temporary disruption of a 
medicine’s marketing 
It is de facto considered to be a shortage as soon as it lasted for at least 
2 weeks (5). 
Peru “Supply shortage” 
 
 
 
 
Considered as an operational definition in the management of drug 
availability indicators employed by the public bodies within the 
Ministry of Health and Regional Governments. 
 
Essential pharmaceutical products not supplied in the national market. 
                                                 
3 Administración Nacional de Medicamentos, Alimentos y Tecnología Médica. https://www.argentina.gob.ar/anmat 
4 The Therapeutic Goods Administration. Medicine Shortages Information Initiative Available from: 
https://apps.tga.gov.au/prod/MSI/search#furtherinformation 
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Country Terms/concepts 
 
Definition 
Unavailable Pharmaceutical Products 
 
 
Pharmaceutical product with limited supply 
 
Product with limited provision in the pharmaceutical market, which 
could generate access problems (availability and affordability) for the 
population 
Spain Supply problem The Spanish Agency for Medicines and Health Products (Spanish 
acronym: AEMPS), being part of the Spanish Ministry of Health Care, 
defined the “supply problem” as a situation in which the number of 
available units of a drug in the pharmaceutical trade channel is below 
the level of national or local consumption needs, being often due to 
problems in the manufacturing or distribution of a drug 
United States Medicines shortages “A period of time when the demand or projected demand for a 
medically necessary drug in the United States exceeds its supply” 
(Center for Drug Evaluation and research 2018). 
Uruguay Declaration of interruption of sale 
 
Interruption of marketing 
Interruptions lasting 30 days or more. 
 
due to exceptional interruptions by the manufacturer lasting less than 
30 days, which must be communicated to and validated by the 
Department of Medicines. (4) 
  
  
Table 5. Frequency of update on the publicly available databases to report medicines shortages  
 
Frequency of 
updating 
Country 
Organization in charge of 
database 
Access 
Frequency of update 
 
Mandatory Reporting 
 
High 
Australia Therapeutics Goods 
Administration 
https://apps.tga.gov.au/prod/
MSI/search 
Daily Yes 
Belgium Federal Agency of Medicines 
and Health Products 
https://banquededonneesmedi
caments.fagg-
afmps.be/#/query/supply-
problem-history/human 
Daily (this is nominal 
frequency, which may 
be different) 
Yes 
Canada Bell Canada under contract 
with Health Canada 
www.drugshortagescanada.ca
/ 
Daily Yes 
Czech 
Republic 
State Institute for drug control http://www.sukl.eu/dodavky-
leciv-se-zamerenim-na-
lecive-latky 
Daily Yes 
Latvia State Agency of Medicines 
(SAMLV) 
https://www.zva.gov.lv//?id=
781&lang=&top=334&sa=67
3 
Daily Yes 
Portugal [1] Portugal ANF - National 
Association of Pharmacies 
(ANF - Associação Nacional 
de Farmécias) 
https://www.anfonline.pt/ 
 
Daily Yes 
Sweden Swedish  medical products 
agency 
https://lakemedelsverket.se/O
VRIGA-
SIDOR/Restnoteringar/ 
As soon as posible Yes 
US American Society of Health 
Systems Pharmacist - ASHP 
 
https://www.ashp.org/drug-
shortages/current-shortages 
Daily Not 
Medium 
Austria Austrian Medicines and 
Medical Devices Agency 
(AGES MEA) 
www.basg.gv.at/news-
center/news/news-
detail/article/uebersichtslist
e-
vertriebseinschraenkungen-
986/ 
Weekly  
Hungary National Institute of Pharmacy 
and Nutrition 
https://www.ogyei.gov.hu/te
mporary_discontinuation_o
f_sale_/  
Weekly Yes 
Italy Italian Medicines Agency 
(AIFA ‒ Agenzia Italiana del 
35ármaco) 
http://www.aifa.gov.it/content
/carenze-e-
indisponibilt%C3%A0 
Weekly Yes 
Malta [1] Ministry for Health (CPSU ‒ 
Central Procurement and 
Supplies Unit) 
https://health.gov.mt/en/cps
u/Pages/POYC-OOS.aspx 
Weekly Yes 
Norway  
Norwegian Medicines Agency 
https://legemiddelverket.no/le
gemiddelmangel/legemiddelm
angel-og-avregistreringer-
2017-rad-til-apotek-og-
helsepersonell  
Weekly Yes 
Slovakia The State Institute for Drug 
Control (SUKL) 
http://www.sukl.sk/en/inspect
ion/post-authorization-
quality-control/export-of-
medicinal-products/list-of-
medicinal-products-for-
which-they-were-issued-
decisions-not-to-allow-the-
export-from-slovak-
republic?page_id=4006 
Weekly Yes 
Spain [2] Center for Information on 
Medicines Supply (in Spanish: 
Centro de Información sobre 
el Suministro de 
Medicamentos; CISMED) 
http://www.portalfarma.co
m/Profesionales/consejoinfo
rma/Paginas/Infarma-2016-
CISMED.aspx 
Weekly Yes 
Switzerland 
[1] 
Federal Office of Public 
Health  
https://www.bag.admin.ch/b
ag/de/home/themen/mensch-
gesundheit/biomedizin-
forschung/heilmittel/sicherh
eit-in-der-
Weekly  Yes 
  Running Title 
 
36 
This is a provisional file, not the final typeset article 
medikamentenversorgung.h
tml?_organization=317 
Switzerland 
[2] 
Federal Office for national 
economic supply (FONES) 
https://www.bwl.admin.ch/bw
l/de/home.html) 
Weekly Yes 
Switzerland 
[3] 
Swissmedic (Swiss Agency 
for Therapeutic Products) 
https://www.swissmedic.ch/m
arktueberwachung/00135/001
36/00140/00142/index.html?l
ang=de 
Weekly Yes 
Switzerland 
[4] 
Martinelli Consulting 
Switzerland 
www.drugshortage.ch Weekly Not  applicable (private and 
voluntary but highly effective 
initiative) 
Turkey Turkish Medicines and 
Medical Devices Agency: 
TMMDA (in Turkish: Türkiye 
Ilaç Ve Tibbi Cihaz Kurumu; 
TİTCK) 
http://www.titck.gov.tr/ Weekly Yes 
Low 
Argentina National Administration of 
Medicines, Food and Medical 
Technology (ANMAT) 
https://www.argentina.gob.a
r/faltante-de-medicamentos 
Twice a month Yes 
Croatia Croatian Health Insurance 
Fund 
http://www.hzzo.hr/zdravst
veni-sustav-rh/trazilica-za-
lijekove-s-vazecih-lista/  
Monthly Yes 
France [1] French Agency for Medicines 
Safety (ANSM ‒ Agence 
Nationale pour la Sécurité du 
Medicament) 
http://ansm.sante.fr/Mediathe
que/Publications/Information-
in-English 
Yearly Yes 
France [2] National Council of the 
College of Pharmacists 
(Conseil national de l’ordre 
national des pharmaciens ‒ 
CNOP) 
http://www.ordre.pharmaci
en.fr/Le-Dossier-
Pharmaceutique/Ruptures-
d-approvisionnement-et-
DP-Ruptures 
Monthly Yes 
 
Lithuania 
State Medicines Control 
Agency (SMCA) 
www.vvkt.lt Biweekly Undeterminate 
Greece National Organization for 
Medicines (EOF) 
http://www.eof.gr/web/guest/
eparkeia 
Monthly (this is usual 
frequency) 
Yes 
Ireland [1] Irish Pharmaceutical Union 
(IPU) 
https://ipu.ie/home/ipu-
product-file/medicine-
shortages/ 
Minimum monthly, but 
on demand based on 
completion of 
medicines shortages 
notification form 
Yes 
Poland Ministry of Health http://www.bip.mz.gov.pl/le
gislacja/akty-
prawne/obwieszczenie-
ministra-zdrowia-z-dnia-10-
stycznia-2017-r-w-sprawie-
wykazu-produktow-
leczniczych-srodkow-
spozywczych-specjalnego-
przeznaczenia-
zywieniowego-oraz-
wyrobow-medycznych-
zagrozonych-brakiem/ 
At least bimonthly Yes 
Unespecified 
 
Brazil National Health Surveillance 
Agency (ANVISA) 
http://portal.anvisa.gov.br/d
escontinuacao-de-
medicamentos 
As necessary (after 
every notification by 
MAH 
Yes 
Bulgary Bulgarian Drug Agency http://www.bda.bg/bg/ As requiered Not know 
Colombia [1] 
(may 2018 
until now) 
National Institute of Food and 
Medicines Surveillance 
(INVIMA) 
https://www.invima.gov.co/
desabastecimiento-de-
medicamentos 
As required Yes 
Colombia [2] 
(2012 until 
april 2018) 
Ministry of Health https://www.minsalud.gov.c
o/salud/MT/Paginas/desabas
tecimiento.aspx 
As required Yes 
Denmark Danish Medicines Agency https://laegemiddelstyrelsen.d
k/da/godkendelse/kontrol-og-
inspektion/alvorlige-
forsyningsvanskeligheder/# 
As required Yes 
Estonia Estonian State Agency of 
Medicines 
http://www.ravimiamet.ee/ule
vaatlik-tabel-humaanravimite-
tarneraskustest 
As necessary (after 
every notification by 
MAH) 
Yes 
Finland The Finnish Medicines 
Agency - Fimea 
https://www.fimea.fi/tietoa_fi
measta/ajankohtaista/saatavuu
shairiotiedotteet 
As required Yes 
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Germany Instituto Federal de 
Medicamentos y Dispositivos 
Médicos 
https://www.bfarm.de/DE/Bf
ArM/_node.html 
As required Yesit 
Israel Ministry of Health www.health.gov.il According to the need Yes 
Ireland [1] UniPhar www.uniphar.ie As required Yes 
Kosovo Kosovo Medicines Agency www.akppm.com ‒ No 
Malta [1] Ministry for Health (CPSU ‒ 
Central Procurement and 
Supplies Unit) 
https://health.gov.mt/en/cps
u/Pages/Items-Problematic-
To-Source.aspx 
As required Yes 
Republic of 
Srpska, 
Bosnia and 
Herzegovina 
The Agency for Medicinal 
Products and Medical Devices 
of Bosnia and Herzegovina 
(ALMBIH) 
http://www.almbih.gov.ba/vij
esti/ 
As soon as the 
ALMBIH is informed 
by the MAH about 
shortage of a given 
medicine 
Yes 
Romania National Agency for 
Medicines and Medical 
Devices 
https://www.anm.ro/en/ As required Yes 
Spain [1] Spanish Agency of Medicines 
and Health Products 
(AEMPS), being part of the 
Spanish Ministry of Health 
https://cima.aemps.es/cima/fic
hasTecnicas.do?metodo=busc
arDesabastecidos 
As required (whenever 
a shortage is detected) 
Yes 
Slovenia Agency for Medicinal 
Products and Medical Devices 
(JAZMP), and Health 
Insurance Institute of Slovenia 
http://www.jazmp.si/fileadm
in/datoteke/seznami/SFE/Pr
isotnost/Seznam_44_HUM_
prenehanja_motnje.pdf 
www.cbz.si 
Irregular Yes 
United 
Kingdom 
Specialist pharmacy service https://www.sps.nhs.uk/ As needed Yes 
Uruguay Ministry of Public Health https://tramites.gub.uy/amp
liados?id=2659 
As needed Yes 
US [2] Food and Drug Administration  https://www.accessdata.fda.
gov/scripts/drugshortages/ 
Not specified Not 
